Niagen Bioscience, Inc.
NAGENasdaq
$3.28
↓ -3.5%Jul 17 close · end-of-day
Price
1Y↓ -71.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$277.4M
Enterprise Value
$277.4M
P/E
15.6
P/S
2.1
P/B
3.4
EV/EBITDA
20.3
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$130.4M
Net Income (TTM)
$18.6M
Free Cash Flow (TTM)
—
Gross Margin
64.3%
Operating Margin
10.0%
Net Margin
14.3%
ROE
22.6%
ROIC
15.0%
Debt / Equity
—
Net Cash
—
Return 1Y
-68.3%
Company profile
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. It researches on nicotinamide adenine dinucleotide (NAD+) and develops and commercializes proprietary-based ingredient technologies. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform.
- CEO
- Robert N. Fried
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- California
- Website
- chromadex.com
Management & directors
- Fried Robert NChief Executive Officer
- Lopez Carlos LuisSVP, General Counsel
- Pamir OzanChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
NAGE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$31.5M↑ +3.3%
Diluted EPS$0.07↑ +16.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $59.3M | $67.4M | $72.0M | $83.6M | $99.6M | $129.4M |
| Gross profit | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| Operating income | -$19.9M | -$27.1M | -$18.6M | -$5.6M | $7.7M | $16.3M |
| Net income | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.6M | $17.4M |
| Diluted EPS | -$0.33 | -$0.40 | -$0.24 | -$0.07 | $0.11 | $0.20 |
| Operating cash flow | -$10.6M | -$24.2M | -$15.1M | $7.1M | $12.1M | $13.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating margin | -33.5% | -40.1% | -25.9% | -6.7% | 7.8% | 12.6% |
| Net margin | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.7M | $25.6M | $29.1M | $30.5M | $31.1M | $34.0M | $33.8M | $31.5M |
| Gross profit | $13.7M | $16.2M | $18.2M | $19.3M | $20.2M | $21.9M | $21.7M | $20.0M |
| Operating income | -$256,000.00 | $1.6M | $7.1M | $4.8M | $3.2M | $4.2M | $4.1M | $1.6M |
| Net income | -$15,000.00 | $1.9M | $7.2M | $5.1M | $3.6M | $4.6M | $4.1M | $6.3M |
| Diluted EPS | $0.00 | $0.02 | $0.10 | $0.06 | $0.04 | $0.05 | $0.05 | $0.07 |
| Operating cash flow | -$264,000.00 | $3.5M | $8.6M | $7.9M | $1.3M | $3.7M | $679,000.00 | -$1.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 60.2% | 63.5% | 62.5% | 63.4% | 65.0% | 64.5% | 64.1% | 63.5% |
| Operating margin | -1.1% | 6.3% | 24.4% | 15.7% | 10.2% | 12.5% | 12.1% | 5.0% |
| Net margin | -0.1% | 7.3% | 24.6% | 16.6% | 11.6% | 13.5% | 12.2% | 20.1% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Pamir Ozan· Chief Financial Officer | Award | 4,255 | $2.71 | $11,531.05 | filing |
| 2026-06-30 | Lopez Carlos Luis· SVP, General Counsel | Award | 2,314 | $2.71 | $6,270.94 | filing |
| 2026-06-30 | Fried Robert N· Chief Executive Officer | Award | 1,106 | $2.71 | $2,997.26 | filing |
| 2026-04-24 | Fried Robert N· Chief Executive Officer | Option exercise | 20,000 | $2.61 | $52,200.00 | filing |
| 2025-11-14 | Pamir Ozan· Chief Financial Officer | Buy | 4,465 | $6.81 | $30,406.39 | filing |
| 2025-11-14 | Pamir Ozan· Chief Financial Officer | Buy | 2,220 | $6.85 | $15,210.03 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.